Gestiva Passes Cmte. Review, But Further Study Of Miscarriage Risk Requested

FDA’s Reproductive Health Advisory Committee votes that safety and efficacy of Adeza’s preterm birth agent Gestiva have been demonstrated.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet